TQB 3915
Alternative Names: TQB-3915Latest Information Update: 12 Jul 2022
Price :
$50 *
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action Estrogen receptor alpha antagonist
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 13 Jun 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, In adults, In the elderly, Metastatic disease) in China (PO) (NCT05416359)